Skip to content
Tech News
← Back to articles

Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

2026-09-15 | original
read original get Evvy Vaginal Microbiome Test Kit → more articles
Why This Matters

Evvy's $40M raise highlights the growing investor interest in women's health tech, particularly startups tackling long-standing data gaps in female biology. By combining at-home diagnostic testing with a growing proprietary dataset on the vaginal microbiome, Evvy aims to enable more personalized care and fuel new research, addressing a space historically underserved by both medicine and AI models trained on incomplete health data.

Key Takeaways
Worth a Look

Evvy Vaginal Microbiome Test Kit — If you're curious about the at-home testing technology discussed in this article, Evvy's vaginal microbiome test lets you send a single swab to their lab for detailed mNGS analysis. It's a direct way to engage with the same personalized health data and clinician-reviewed insights that fueled this company's growth and research breakthroughs.

See Evvy Vaginal Microbiome Test Kit on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.

Women’s health company Evvy on Tuesday said it has raised a $40 million Series B led by Catalio Capital Management.

Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, the company is best known for operating what it touts as the world’s only at-home CLIA-certified and CLEP-certified mNGS test to analyze vaginal microbes with one swab.

The user mails their swab samples to Evvy’s lab, which then analyzes the results using its own mNGS sequencing, sends them to clinicians registered on its platform for review, and posts the results online in the patient’s health portal.

“When a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant,” CEO and co-founder Priyanka Jain told TechCrunch.

Since its launch, Evvy says it now serves more than 100,000 patients across the United States, and works with 3,000 practitioners. “We’ve generated 15 peer-reviewed publications and abstracts, identified novel BV subtypes, and discovered hundreds of previously uncatalogued vaginal microbiome genomes,” Jain said.

She added that clinicians on Evvy can now leverage the collected data to offer personalized treatment to patients.

But treating patients is only one part of the company’s vision. Its bigger goal is to build a dataset that connects microbiome biology, symptoms, interventions, and health outcomes, “creating a continuous feedback loop that unlocks improvements to care and the discovery of entirely new biomarkers,” Jain said.

There is a fundamental flaw right now with precision medicine: the lack of high-quality, representative data on female bodies. “You can’t build precision medicine for women on datasets that never adequately measured female biology in the first place,” Jain said, citing how leading AI models often struggle to answer questions about women’s health.

“That’s why I believe AI for women’s health needs to be paired with new biological data at scale. AI can help us identify patterns across molecular signals, hormones, symptoms, treatments, fertility outcomes, and other biomarkers that traditional medicine has struggled to connect.”

In May, the company started offering its own AI assistant called EvvyAI, which it bills as an advisor for vaginal health. It translates the microbiome data that Evvy has collected into real-time guidance for users, and directs patients to clinicians for questions that need expert opinions.

... continue reading

Explore topics: evvy vaginal microbiome women's health catalio capital management priyanka jain

© 2026 GoKawiil

About | Editorial Policy | Contact | Email Alerts